GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » ROCE %

ARTV (Artiva Biotherapeutics) ROCE % : -52.88% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Artiva Biotherapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -52.88%.

Artiva Biotherapeutics ROCE % Historical Data

The historical data trend for Artiva Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics ROCE % Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
- -130.03 -82.51 -46.37 -30.62

Artiva Biotherapeutics Quarterly Data
Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -51.55 -67.14 -89.40 -52.88

Artiva Biotherapeutics ROCE % Calculation

Artiva Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-30.671/( ( (133.054 - 25.625) + (105.114 - 12.227) )/ 2 )
=-30.671/( (107.429+92.887)/ 2 )
=-30.671/100.158
=-30.62 %

Artiva Biotherapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-73.34/( ( (75.912 - 10.827) + (225.596 - 13.292) )/ 2 )
=-73.34/( ( 65.085 + 212.304 )/ 2 )
=-73.34/138.6945
=-52.88 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artiva Biotherapeutics  (NAS:ARTV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Artiva Biotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Artiva Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » ROCE %
Comparable Companies
Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Website
https://www.artivabio.com
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.